Patents Examined by David W Berke-Schlessel
-
Patent number: 11987806Abstract: The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth.Type: GrantFiled: April 22, 2022Date of Patent: May 21, 2024Assignee: Cellum Biomedical, Inc.Inventor: Richard C. Jin
-
Patent number: 11987807Abstract: Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.Type: GrantFiled: November 24, 2021Date of Patent: May 21, 2024Assignee: The General Hospital CorporationInventors: Jayaraj Rajagopal, Hongmei Mou
-
Patent number: 11986500Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.Type: GrantFiled: December 18, 2023Date of Patent: May 21, 2024Assignee: REBIOTIX INCInventor: Edwin J. Hlavka
-
Patent number: 11985969Abstract: This disclosure describes a cryopreservative composition and methods for storing cells. Generally, the cryopreservative composition includes a sugar component and a sugar alcohol component, and is effective for storing and recovering cells without requiring dimethyl sulfoxide (DMSO).Type: GrantFiled: July 9, 2021Date of Patent: May 21, 2024Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Allison Hubel, Kathryn Lindsay Pollock
-
Patent number: 11981948Abstract: Described herein are engineered organelles comprising multi-component proteins from different species incorporated into a membrane structure with interior and exterior aspects. In one embodiment the artificial organelle incorporates one or more protein complexes that absorb optical energy and catalyze electron transfer in biochemical reactions that can be used to reduce NAD+ to NADH or analogues thereof.Type: GrantFiled: November 2, 2022Date of Patent: May 14, 2024Assignee: Ensovi, Inc.Inventors: Kyle A Minor, Carlo D. Montemagno, David W. Wendell
-
Patent number: 11981919Abstract: The present invention relates to the field of stem cells. More specifically, the invention provides methods and compositions useful for forming three-dimensional human retinal tissue in vitro. In a specific embodiment, an in vitro method for differentiating hiPSCs into three-dimensional retinal tissue comprising functional photoreceptors comprises the steps of (a) culturing the hiPSCs to form aggregates; (b) transitioning the aggregates into a neural induction medium; (c) seeding the aggregates on to extracellular matrix coated cell culture substrates; (d) replacing NIM with a chemically-defined differentiation medium; (e) detaching NR domains; (f) culturing in suspension; and (g) adding animal serum or plasma component and retinoic acid.Type: GrantFiled: April 3, 2020Date of Patent: May 14, 2024Assignee: The John Hopkins UniversityInventors: Maria Valeria Canto-Soler, Xiufeng Zhong
-
Patent number: 11980698Abstract: Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.Type: GrantFiled: June 1, 2021Date of Patent: May 14, 2024Assignees: Arizona Board of Regents on Behalf of the University of Arizona, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Jordan J. Lancaster, Steven Goldman
-
Patent number: 11976295Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.Type: GrantFiled: January 12, 2023Date of Patent: May 7, 2024Assignee: MINERVA BIOTECHNOLOGIES CORPORATIONInventors: Cynthia Bamdad, Benoit Smagghe
-
Patent number: 11975027Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.Type: GrantFiled: November 30, 2021Date of Patent: May 7, 2024Assignee: ImmunityBio, Inc.Inventors: Hans G. Klingemann, Barry J. Simon
-
Patent number: 11976298Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.Type: GrantFiled: September 19, 2018Date of Patent: May 7, 2024Assignee: Targazyme, Inc.Inventors: Stephen D. Wolpe, Leonard Miller, Lynnet Koh, Thomas E. Ichim
-
Patent number: 11970724Abstract: The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.Type: GrantFiled: July 8, 2021Date of Patent: April 30, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Shadia Abike Oshodi, Amy S. Johnson, Shawn M. Lawrence
-
Patent number: 11965199Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: GrantFiled: January 31, 2022Date of Patent: April 23, 2024Assignee: SANOFIInventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Patent number: 11952559Abstract: This present disclosure relates to novel detergent compositions comprising bacterial mannanase enzymes. The detergent compositions comprising bacterial mannanases are useful in laundry and cleaning applications wherein degradation or modification of mannan is desired. The present disclosure also relates to the use of said detergent compositions in laundry and cleaning applications as well as a method for degrading mannan.Type: GrantFiled: March 1, 2018Date of Patent: April 9, 2024Assignee: AB Enzymes OyInventors: Daniela Herbst, Susanne Wieland, Nina Mussmann, Taija Leinonen, Leena Valtakari, Michael Seefried, Kari Juntunen, Daniela Dollak, Patrick Lorenz, Jari Vehmaanperae, Pentti Ojapalo, Terhi Puranen, Kristiina Jaervinen
-
Patent number: 11952592Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.Type: GrantFiled: February 23, 2022Date of Patent: April 9, 2024Assignee: EMULATE, INC.Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
-
Patent number: 11952603Abstract: A pancreatin preparation having reduced viral infectivity includes one or more pancreatin enzymes and peracetic acid (PAA). At least one pancreatin enzyme may be derived from an animal source such as a porcine pancreas gland. In a particular embodiment, the one or more pancreatin enzymes are selected from the group consisting of lipases, proteases, and amylases.Type: GrantFiled: August 22, 2018Date of Patent: April 9, 2024Assignee: SCIENTIFIC PROTEIN LABORATORIES, LLCInventors: Kenneth S. Manning, Yan Wang, Dustin Nielsen, Ryan Ruf, Colin Crowley, Jon Restivo, Dana Spangenberg, Karla Anhalt, Mark Romich, Anisha Akula, Carmen Fritz
-
Patent number: 11944651Abstract: The present invention aims to provide an antimicrobial and antiviral agent which comprises a naturally occurring component as an active ingredient and is effective against microbes including various classes of fungi and viruses. In one aspect of the present invention, provided is an antimicrobial and antiviral agent comprising Lactobacillus derived from Artemisia indica var. maximowiczii.Type: GrantFiled: September 8, 2021Date of Patent: April 2, 2024Assignee: Murata Manufacturing Co., Ltd.Inventors: Masachika Takata, Hirofumi Sunahara
-
Patent number: 11945795Abstract: Disclosed herein are compositions and methods useful for manufacturing SC-? cell, and isolated populations of SC-? cells for use in various applications, such as cell therapy.Type: GrantFiled: May 1, 2020Date of Patent: April 2, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Austin Thiel, Jihad Yasin, Evrett Thompson, Felicia J. Pagliuca
-
Patent number: 11946853Abstract: A apparatus for detecting cells or particles in a fluid container includes a dispenser configured to dispense at least one cell or at least one particle into a defined sub-volume of a fluid with which the fluid container is at least partially filled, and a detection apparatus configured to, in a time-coordinated manner with dispensing the at least one cell or the at least one particle by the dispenser, perform a detection in the defined sub-volume and/or in one or several sub-volumes underneath the defined sub-volume in order to sense the at least one cell or the at least one particle when entering the fluid or immediately after entering the fluid.Type: GrantFiled: August 6, 2021Date of Patent: April 2, 2024Assignee: cytena GmbHInventors: Jonas Schoendube, Andre Gross
-
Patent number: 11944654Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.Type: GrantFiled: August 11, 2022Date of Patent: April 2, 2024Assignee: Rebiotix, Inc.Inventor: Edwin J. Hlavka
-
Patent number: 11940442Abstract: The current technology is related to methods for rapidly determining the metabolic baseline and potential of living cells. Embodiments relate to measuring the activity of each of the two major energy-generating pathways within the cell: mitochondrial respiration and glycolysis, first under baseline conditions, and again after applying a stress to the cells to demand increased energy supply. In some embodiments the stress may be applied by exposing the cells to a combination of two chemical compounds: a mitochondrial uncoupler and an ATP synthase inhibitor. In one embodiment, the metabolic energy generating activity of the mitochondrial respiration pathway is determined by measuring the rate of oxygen consumption by the living cells, and the metabolic energy generating activity of the glycolysis pathway is determined from a measurement of extracellular acidification caused by secretion of protons from the cell.Type: GrantFiled: June 30, 2020Date of Patent: March 26, 2024Assignee: Agilent Technologies, Inc.Inventors: David A. Ferrick, Brian Dranka